|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 290.39 USD | -1.39% |
|
+1.06% | -17.70% |
| 06-30 | United Therapeutics' Tyvaso to Benefit from Q2 Seasonality, UBS Says | MT |
| 06-30 | UBS Adjusts Price Target on United Therapeutics to $385 From $410, Maintains Buy Rating | MT |
Sales 2024 by Business Segment
Sales 2024 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Pharmaceuticals | 1.48B | 1.69B | 1.94B | 2.33B | 2.88B | |||||
Total Assets | 4.62B | 5.17B | 6.04B | 7.17B | 7.36B | |||||
Interest Expense | -23.5M | -18.6M | -32.4M | -59.3M | -42.9M | |||||
Income Tax Expense | 124M | 118M | 223M | 290M | 344M | |||||
CAPEX | -59.3M | -121M | -139M | -230M | -246M | |||||
EBT | 639M | 594M | 951M | 1.27B | 1.54B | |||||
D&A | 49.9M | 49.9M | 51.3M | 53.2M | 72.5M | |||||
Operating Income | 594M | 556M | 980M | 1.18B | 1.38B | |||||
Net Income | 515M | 476M | 727M | 985M | 1.2B |
Geographical Revenue Distribution History
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
United States | 1.41B | 1.56B | 1.81B | 2.2B | 2.74B | |||||
Total Assets | 717M | 768M | 871M | 1.06B | 1.24B | |||||
Rest of World | 71.2M | 121M | 122M | 125M | 138M | |||||
Total Assets | 14.3M | 12.8M | 12.6M | 12M | 11.7M |
- Stock Market
- Equities
- UTHR Stock
- Financials United Therapeutics Corporation
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition